USA - NASDAQ:SMTI - US79957L1008 - Common Stock
The current stock price of SMTI is 31.82 USD. In the past month the price decreased by -7.96%. In the past year, price increased by 3.62%.
Symbol | Company Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ALC | ALCON INC | 24.48 | 36.95B | ||
COO | COOPER COS INC/THE | 16.84 | 13.46B | ||
SOLV | SOLVENTUM CORP | 11.78 | 12.42B | ||
ALGN | ALIGN TECHNOLOGY INC | 13.45 | 9.18B | ||
BLCO | BAUSCH + LOMB CORP | 35.1 | 5.22B | ||
MMSI | MERIT MEDICAL SYSTEMS INC | 22.03 | 4.77B | ||
LNTH | LANTHEUS HOLDINGS INC | 8 | 3.48B | ||
ICUI | ICU MEDICAL INC | 15.74 | 2.92B | ||
XRAY | DENTSPLY SIRONA INC | 7.26 | 2.48B | ||
HAE | HAEMONETICS CORP/MASS | 10.38 | 2.32B | ||
UFPT | UFP TECHNOLOGIES INC | 22.37 | 1.49B | ||
STAA | STAAR SURGICAL CO | N/A | 1.32B |
Sanara MedTech, Inc. engages in the development, marketing, and distribution of biotechnology products to physicians, hospitals, and clinics. The company is headquartered in Fort Worth, Texas and currently employs 141 full-time employees. Its Sanara Surgical segment primarily markets and sells soft tissue repair and bone fusion products for use in the operating room or other sterile environments. Its Tissue Health Plus segment is focused on value-based wound care services. The company markets and distributes CellerateRX Surgical Activated Collagen, FORTIFY TRG Tissue Repair Graft and FORTIFY FLOWABLE Extracellular Matrix as well as a portfolio of advanced biologic products focusing on ACTIGEN Verified Inductive Bone Matrix, ALLOCYTE Plus Advanced Viable Bone Matrix, BiFORM Bioactive Moldable Matrix, TEXAGEN Amniotic Membrane Allograft, and BIASURGE Advanced Surgical Solution to the surgical market. BIAKOS Antimicrobial Wound Gel and others are the products sold in the wound care market.
SANARA MEDTECH INC
1200 Summit Avenue, Suite 414
Fort Worth TEXAS 76102 US
CEO: Ronald T. Nixon
Employees: 141
Phone: 18175292300
The current stock price of SMTI is 31.82 USD. The price increased by 1.86% in the last trading session.
The exchange symbol of SANARA MEDTECH INC is SMTI and it is listed on the Nasdaq exchange.
SMTI stock is listed on the Nasdaq exchange.
8 analysts have analysed SMTI and the average price target is 51 USD. This implies a price increase of 60.28% is expected in the next year compared to the current price of 31.82. Check the SANARA MEDTECH INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
SANARA MEDTECH INC (SMTI) has a market capitalization of 283.20M USD. This makes SMTI a Micro Cap stock.
SANARA MEDTECH INC (SMTI) currently has 141 employees.
SANARA MEDTECH INC (SMTI) has a support level at 31.23 and a resistance level at 33.65. Check the full technical report for a detailed analysis of SMTI support and resistance levels.
The Revenue of SANARA MEDTECH INC (SMTI) is expected to grow by 22.74% in the next year. Check the estimates tab for more information on the SMTI EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
SMTI does not pay a dividend.
SANARA MEDTECH INC (SMTI) will report earnings on 2025-11-10.
SANARA MEDTECH INC (SMTI) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.16).
The outstanding short interest for SANARA MEDTECH INC (SMTI) is 7.53% of its float. Check the ownership tab for more information on the SMTI short interest.
ChartMill assigns a technical rating of 5 / 10 to SMTI. When comparing the yearly performance of all stocks, SMTI turns out to be only a medium performer in the overall market: it outperformed 59.81% of all stocks.
ChartMill assigns a fundamental rating of 4 / 10 to SMTI. While SMTI seems to be doing ok healthwise, there are quite some concerns on its profitability.
Over the last trailing twelve months SMTI reported a non-GAAP Earnings per Share(EPS) of -1.16. The EPS decreased by -48.97% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -10.04% | ||
ROE | -28.4% | ||
Debt/Equity | 1.26 |
8 analysts have analysed SMTI and the average price target is 51 USD. This implies a price increase of 60.28% is expected in the next year compared to the current price of 31.82.
For the next year, analysts expect an EPS growth of 12.32% and a revenue growth 22.74% for SMTI